XBIO vs. GDTC, BIOR, COCP, BFRG, SLGL, FBRX, CPIX, JAGX, IBIO, and PPBT
Should you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include CytoMed Therapeutics (GDTC), Biora Therapeutics (BIOR), Cocrystal Pharma (COCP), Bullfrog AI (BFRG), Sol-Gel Technologies (SLGL), Forte Biosciences (FBRX), Cumberland Pharmaceuticals (CPIX), Jaguar Health (JAGX), iBio (IBIO), and Purple Biotech (PPBT). These companies are all part of the "pharmaceutical preparations" industry.
CytoMed Therapeutics (NASDAQ:GDTC) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability.
CytoMed Therapeutics has a net margin of 0.00% compared to CytoMed Therapeutics' net margin of -182.99%. Xenetic Biosciences' return on equity of 0.00% beat CytoMed Therapeutics' return on equity.
0.0% of CytoMed Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 9.0% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Xenetic Biosciences received 172 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 68.24% of users gave Xenetic Biosciences an outperform vote.
CytoMed Therapeutics has higher earnings, but lower revenue than Xenetic Biosciences.
In the previous week, Xenetic Biosciences had 1 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 3 mentions for Xenetic Biosciences and 2 mentions for CytoMed Therapeutics. Xenetic Biosciences' average media sentiment score of 1.44 beat CytoMed Therapeutics' score of 1.28 indicating that CytoMed Therapeutics is being referred to more favorably in the media.
CytoMed Therapeutics currently has a consensus target price of $5.00, indicating a potential upside of 131.48%. Given Xenetic Biosciences' higher probable upside, equities research analysts plainly believe CytoMed Therapeutics is more favorable than Xenetic Biosciences.
Summary
CytoMed Therapeutics beats Xenetic Biosciences on 8 of the 13 factors compared between the two stocks.
Get Xenetic Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Xenetic Biosciences Competitors List
Related Companies and Tools
